(480) 360-4610  ·  questions@petepharma.com
Partner portal Pete Pharma + FabRx
Request a sampleBook a demo
TechnologyTechnology overviewThe Pete Pharma ecosystemBuilt-in quality controlM3DIMAKER StudioVideo libraryROI for pharmacies
Dosage formsDosage forms overviewTri-score tabletsIR tabletsER tabletsRapid dissolve / ODTOral film stripsNasal irrigation tabletsAll dosage forms
InnovationInnovation overviewNanoSil™TS-88™Request a sample
BasesResearchAboutContactBook a demoRequest a sample
Research & standards

Backed by peer-reviewed science. Built to compounding standards.

Pharmaceutical 3D printing did not start in a pharmacy. It started in university labs and children’s hospitals, with more than a decade of published work behind every tray the M3DIMAKER prints. These are the papers we point partners to.

Researchers in a formulation laboratory
USP <795> / <797>Formulas and workflows written for compounding practice
Dissolution testedUSP dissolution and potency on every library formula
6-month BUDAnhydrous proprietary bases, no refrigeration
First-in-clinicClinical studies of 3D-printed medicines since 2019

Clinical evidence

3D-printed medicines given to real patients — the studies that moved the technology from the lab to the clinic.

International Journal of Pharmaceutics · 2019Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: first single-centre, prospective, crossover study in patientsGoyanes A, Madla CM, Umerji A, et al.First clinical study of 3D-printed personalised medicines, in children with maple syrup urine disease.International Journal of Pharmaceutics · 2024Paediatric clinical study of 3D printed personalised medicines for rare metabolic disordersRodríguez-Pombo L, et al.Hospital-prepared 3D-printed chewable tablets for children with rare metabolic disorders.

The printing technology

How tablets are built layer by layer, and how geometry and process control release.

International Journal of Pharmaceutics · 2014Fused-filament 3D printing (3DP) for fabrication of tabletsGoyanes A, Buanz ABM, Basit AW, Gaisford S.The paper that started it — the first 3D-printed drug-loaded tablets by extrusion.International Journal of Pharmaceutics · 2015Effect of geometry on drug release from 3D printed tabletsGoyanes A, Robles Martinez P, Buanz A, Basit AW, Gaisford S.Why the shape of a printed tablet sets its dissolution — the basis of cavity-engineered release.European Journal of Pharmaceutics and Biopharmaceutics · 20153D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tabletsGoyanes A, Buanz ABM, Hatton GB, Gaisford S, Basit AW.International Journal of Pharmaceutics · 2019Direct powder extrusion 3D printing: fabrication of drug products using a novel single-step processGoyanes A, Allahham N, Trenfield SJ, Stoyanov E, Gaisford S, Basit AW.Single-step printing straight from powder — the approach behind the M3DIMAKER's direct extrusion head.International Journal of Pharmaceutics · 2017Selective laser sintering (SLS) 3D printing of medicinesFina F, Goyanes A, Gaisford S, Basit AW.

Patients and acceptability

What patients — including children — make of printed tablets.

International Journal of Pharmaceutics · 2017Patient acceptability of 3D printed medicinesGoyanes A, Scarpa M, Kamlow M, Gaisford S, Basit AW, Orlu M.Pharmaceutics · 2020I spy with my little eye: a paediatric visual preferences survey of 3D printed tabletsJanuskaite P, Xu X, Ranmal SR, et al.

Reviews and the road ahead

Where 3D-printed pharmaceuticals stand, and what it takes to put them into practice.

Advanced Drug Delivery Reviews · 2021Translating 3D printed pharmaceuticals: from hype to real-world clinical applicationsSeoane-Viaño I, Trenfield SJ, Basit AW, Goyanes A.Trends in Pharmacological Sciences · 20183D printing pharmaceuticals: drug development to frontline careTrenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW.Drug Discovery Today · 2018Reshaping drug development using 3D printingAwad A, Trenfield SJ, Goyanes A, Gaisford S, Basit AW.
Credibility

The M3DIMAKER platform was developed by FabRx, founded by world experts in pharmaceutical 3D printing from University College London, and refined over a decade with collaborators including Great Ormond Street Hospital, Vall d’Hebron University Hospital, Erasmus MC, the University of Cambridge, Monash University, Pfizer and AstraZeneca. Its first clinical studies of 3D-printed personalised medicines were published in 2019. Pete Pharma brings the platform, validated formulas and bases to U.S. compounding.

Full publication list on Google Scholar →The technology
Next step

Want the evidence for a specific dosage form?

Ask us for the dissolution data and references behind any formula in the library.

Book a live demoAsk a question